Xenetic Biosciences (XBIO)

• Market cap: $6.53M
• 1 day: 2.89%
• 5 days: -2.73%
• 1 month: -7.77%
• 3 months: -9.81%
• 6 months: 35.07%
• Year to date: 32.56%
• 1 year: -21.92%
• 5 years: -85.16%
• 10 years: -99.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Employees: 2